• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    63.22 -0.48 (-0.75%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,579,992
    Open 64.12
    Bid (Size) 62.24 (1)
    Ask (Size) 63.30 (4)
    Prev. Close 63.70
    Today's Range 62.57 - 64.59
    52wk Range 50.27 - 70.36
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
    From Incyte
    Via Business Wire
    Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
    Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property

    Performance

    YTD
    -3.41%
    -3.41%
    1 Month
    -2.98%
    -2.98%
    3 Month
    +2.38%
    +2.38%
    6 Month
    +10.68%
    +10.68%
    1 Year
    +6.65%
    +6.65%

    More News

    Read More
    Wall Street Lower Ahead Of Interest Rate Move
    Via Talk Markets
    Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
    Via Benzinga
    Analyst Expectations For Incyte's Future
    Via Benzinga
    Analyst Ratings For Incyte
    Via Benzinga
    Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
    From Incyte
    Via Business Wire
    Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
    Via Chartmill
    Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
    From Incyte
    Via Business Wire
    Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
    Via Benzinga
    Exposures Product Safety
    Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
    From Incyte
    Via Business Wire
    FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
    Via Benzinga
    Exposures Product Safety
    Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
    From Incyte and Syndax Pharmaceuticals
    Via Business Wire
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
    Via Benzinga
    Topics Death
    Exposures Death
    Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
    Via Benzinga
    Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.